Loading...
Please wait, while we are loading the content...
Similar Documents
Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II study.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Lippe, Phil Tummarello, Diego Monterubbianesi, Maria Cristina Silva, Rosa Giuliodori, Luciano Mari, Davide Santo, Alessandro Pasini, Francesco Cetto, Gian Luigi Rossi, Dominique Porfiri, Emilio Cascinu, Stefano Cellerino, Riccardo |
| Copyright Year | 1999 |
| Abstract | BACKGROUND The combination of gemcitabine and cisplatin has proven effective in the treatment of advanced non-small-cell lung cancer (NSCLC). However, the optimal schedule for administration of the two drugs has not yet been determined. In this study we evaluated the activity and toxicity of a weekly gemcitabine and cisplatin schedule. PATIENTS AND METHODS Thirty-six untreated patients with stage IIIB IV NSCLC entered the study. Treatment consisted of gemcitabine 1000 mg/m2 i.v. and cisplatin 35 mg/m2 i.v., both given weekly on day 1,8, and 15, followed by one week of rest. RESULTS Ninety-seven courses (273 weekly administrations) were delivered. The median dose-intensity was 612 mg/m2 per week for gemcitabine (82%) and 21 mg/m2 per week for cisplatin (80%). All 36 of the patients were evaluable for toxicity, and 30 for response. Partial remissions were observed in 12 patients, for an overall response rate of 40% (95% confidence interval (95% CI): 22.5%-57.5%). Most of the partial remissions were seen in IIIB patients (54% of the stage IIIB and 22% of the stage IV patients responded). According to the intent-to-treat principle, the response rate was 33.3% (12 of 36 patients). The median response duration was 9.9 months (range 4-23) and the median survival time 11.8 months (range 1-24). World Health Organization (WHO) grade 3-4 myelotoxicity was: thrombocytopenia in nine patients (25%), neutropenia in six (16.6%) and anemia in six (16.6%); there was very little additional major toxicity. CONCLUSIONS This regimen appears to be active and to have a favourable toxicity profile. |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://watermark.silverchair.com/10-2-217.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAakwggGlBgkqhkiG9w0BBwagggGWMIIBkgIBADCCAYsGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMrqpsGOOnctFqhfHsAgEQgIIBXNjux8QaneS3CHowUM_mwwYee1i2fLUPur5PGH31Prk27xWfJ-IC1IJ_Ek35szecvVYuXqSPvum06qHhtFHVf7bPIFJH5i9c2gpKTNpdtARpdyAs_xkDWgwlvFN703jh81g-o5xmnCbzKhBoTD-f051pc7nYOWjOHu5G2U_BlpHt5DkQwgy_iVFlolMwl1qI_Ci7DZxz9H0HX_EmbSLA5kbv8uoqBlJ0aSeT7OCLEYX6WlkdyPgY7pRiDGAC96QYEpGFsZ1TIDrJr8D4ZFwOI793ZQQExExhmALMWKetZ5HSsaZjODt5bTm8ImjVFtpU6wNYY7ucW0pdBIBXvni_hMK39-4-glDgCtDHIYrsTlDZu8Ln-6QiCHomt4wz0uFigo4cbFuwFT5FbHHioASJf-DaKXIv5PFps4S0_09-FHZxhmZMPW8jnYHPPNHSKvfv927ldE2hPVzRFPz4jw |
| PubMed reference number | 10093692v1 |
| Volume Number | 10 |
| Issue Number | 2 |
| Journal | Annals of oncology : official journal of the European Society for Medical Oncology |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Adverse reaction to drug Anemia Bone Marrow Diseases Carcinoma of lung Cisplatin Confidence Intervals Eighty Evaluable Disease Milligram per Square Meter Neutropenia Non-Small Cell Lung Carcinoma One Thousand Patients Thrombocytopenia World Health Organization gemcitabine stage II bladder cancer stage IV childhood Hodgkin's lymphoma |
| Content Type | Text |
| Resource Type | Article |
